Next Article in Journal
The Abscopal Effect in Head-and-Neck Squamous Cell Carcinoma Treated with Radiotherapy and Nivolumab: A Case Report and Literature Review
Previous Article in Journal
Perspectives of Hematology Oncology Clinicians about Integrating Palliative Care in Oncology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 6
10.3747/co.27.7297
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer

by
P.K. Cheema
1,
M. Gomes
2,
S. Banerji
3,
P. Joubert
4,
N.B. Leighl
5,
B. Melosky
6,
B.S. Sheffield
7,
T. Stockley
8 and
D.N. Ionescu
9,*
1
William Osler Health System, University of Toronto, Brampton, ON, Canada
2
The Ottawa Hospital Research Institute and Department of Pathology, University of Ottawa, Ottawa, ON, Canada
3
Research Institute in Oncology and Hematology, CancerCare Manitoba, and Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
4
Princess Margaret Cancer Centre, Toronto, ON, Canada
5
Department of Pathology, Quebec Heart and Lung Institute, Université Laval, Quebec City, QC, Canada
6
BC Cancer–Vancouver Centre, Vancouver, BC, Canada
7
Department of Laboratory Medicine, William Osler Health System, Brampton, ON, Canada
8
Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
9
BC Cancer, Department of Pathology, University of British Columbia, Vancouver, BC V6T 2B5, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(6), 321-329; https://doi.org/10.3747/co.27.7297
Submission received: 10 September 2020 / Revised: 8 October 2020 / Accepted: 11 November 2020 / Published: 1 December 2020

Abstract

The advent of personalized therapy for non-small-cell lung carcinoma (nsclc) has improved patient outcomes. Selection of appropriate targeted therapy for patients with nsclc now involves testing for multiple biomarkers, including EGFR. EGFR mutation status is required to optimally treat patients with nsclc, and thus timely and accurate biomarker testing is necessary. However, in Canada, there are currently no standardized processes or methods in place to ensure consistent testing implementation. That lack creates challenges in ensuring that all appropriate biomarkers are tested for each patient and that the medical oncologist receives the results for making informed treatment decisions in a timely way.An expert multidisciplinary working group was convened to create consensus recommendations about biomarker testing in advanced NSCLC in Canada, with a primary focus on EGFR testing. Recognizing that there are biomarkers beyond EGFR that require timely identification, the expert multidisciplinary working group considered EGFR testing in the broader context of integration into complex lung biomarker testing. Primarily, the panel of experts recommends that all patients with nonsquamous NSCLC, regardless of stage, should undergo comprehensive reflex biomarker testing at diagnosis with targeted next-generation sequencing. The panel also considered the EGFR testing algorithm and the challenges associated with the pre-analytic, analytic, and post-analytic elements of testing. Strategies for funding testing by reducing silos of single biomarker testing for EGFR and for optimally implementing the recommendations presented here and educating oncology professionals about them are also discussed.
Keywords: biomarker testing; comprehensive biomarker testing; non-small-cell lung cancer; NSCLC; targeted therapy; EGFR T790M; epidermal growth factor receptor; EGFR biomarker testing; comprehensive biomarker testing; non-small-cell lung cancer; NSCLC; targeted therapy; EGFR T790M; epidermal growth factor receptor; EGFR

Share and Cite

MDPI and ACS Style

Cheema, P.K.; Gomes, M.; Banerji, S.; Joubert, P.; Leighl, N.B.; Melosky, B.; Sheffield, B.S.; Stockley, T.; Ionescu, D.N. Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Curr. Oncol. 2020, 27, 321-329. https://doi.org/10.3747/co.27.7297

AMA Style

Cheema PK, Gomes M, Banerji S, Joubert P, Leighl NB, Melosky B, Sheffield BS, Stockley T, Ionescu DN. Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology. 2020; 27(6):321-329. https://doi.org/10.3747/co.27.7297

Chicago/Turabian Style

Cheema, P.K., M. Gomes, S. Banerji, P. Joubert, N.B. Leighl, B. Melosky, B.S. Sheffield, T. Stockley, and D.N. Ionescu. 2020. "Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer" Current Oncology 27, no. 6: 321-329. https://doi.org/10.3747/co.27.7297

APA Style

Cheema, P. K., Gomes, M., Banerji, S., Joubert, P., Leighl, N. B., Melosky, B., Sheffield, B. S., Stockley, T., & Ionescu, D. N. (2020). Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung Cancer. Current Oncology, 27(6), 321-329. https://doi.org/10.3747/co.27.7297

Article Metrics

Back to TopTop